Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO project.

doi:10.1016/j.ejca.2026.116728

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO project.

European journal of cancer (Oxford, England : 1990) - 15 May 2026

Sàbat Paula, Ajenjo-Bauza Maria, Hierro Cinta, Ruffinelli José Carlos, Gil-Martin Marta, Ochoa-de-Olza María, Bergamino Milana, Calvo Mariona, Soto-Castillo Juan José, Fina Clàudia, Llop Sandra, Stradella Agostina, Oliva Marc, Notario Lucía, Carcereny Enric, Teixidor-Vilà Eduard, Domènech Marta, Jové Maria, Villanueva Rafael, Alay Ania, Azuara Daniel, González-Acosta Maribel, Otero-Torres Sara, Gausachs Mireia, Varela Mar, Villatoro Sergi, Solanes Ares, Teulé Alexandre, Cuadra Carmen, Moreno Víctor, Nadal Ernest, Cordero David, Lázaro Conxi, Martin-Liberal Juan

Abstract excerpt

BACKGROUND: Next-generation sequencing (NGS) is central to precision oncology. However, its implementation in public healthcare systems is limited by economic and logistical barriers. In 2022, the Catalan Institute of Oncology (ICO) launched the PREICO project to expand access to comprehensive genomic profiling (CGP) beyond publicly funded indications across a cancer center network. METHODS: We analyzed patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Biomarkers, Tumor

Share to BRAF gene

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Neoplasms

Share to Precision Medicine

Source

Open in PubMed

Identifiers

PMID: 41962211
DOI: 10.1016/j.ejca.2026.116728

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Implementing a molecular prescreening strategy for tumors without public NGS access in a cancer center network: Results from the PREICO project.PMID 41962211Read ↗

Feasibility of whole‐genome sequencing‐based tumor diagnostics in routine pathology practiceSemantic proximity Read ↗

First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.Semantic proximity Read ↗

Next-Generation Sequencing in Oncology—A Guiding Compass for Targeted Therapy and Emerging ApplicationsSemantic proximity Read ↗

Utility of public knowledge bases for the interpretation of comprehensive tumor molecular profiling results.Semantic proximity Read ↗

Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.Semantic proximity Read ↗

A single-institution retrospective study of comprehensive genomic profiling tests based on C-CAT findings for advanced solid cancers.Semantic proximity Read ↗

Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study.Semantic proximity Read ↗

Pragmatic Nationwide Master Observational Trial Based on Genomic Alterations in Advanced Solid Tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II Study Protocol KCSG AL-22-09Semantic proximity Read ↗

Comprehensive genomic profiling for oncological advancements by precision medicine.Semantic proximity Read ↗

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsSemantic proximity Read ↗

Clinical Tumor Sequencing: Opportunities and Challenges for Precision Cancer MedicineSemantic proximity Read ↗

Comprehensive Genomic Profiling in Metastatic Solid Tumors: High Actionability But Low Implementation in Real-World PracticeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.